Status:
COMPLETED
Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
Phase:
PHASE3
Brief Summary
Long term efficacy of exemestane as compared to megestrol acetate in the treatment of women with natural or induced postmenopausal status with advanced breast cancer whose disease has progressed follo...
Eligibility Criteria
Inclusion
- Previous participation in study 971-ONC-0028-080.
Exclusion
- Subjects who had not previously participated in study 971-ONC-0028-080.
Key Trial Info
Start Date :
November 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT01237327
Start Date
November 1 2001
End Date
December 1 2009
Last Update
May 6 2011
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, China, 100021
2
PLA 307 Hospital
Beijing, China, 100039
3
Ba Yi Hospital, Cancer Center of CPLA
Nanjing, China, 210002
4
Jiangsu Cancer Hospital
Nanjing, China, 210009